Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 20/20 | 0.94 |
| ▸ | JAK2 | O60674 | 2/20 | 0.75 |
| ▸ | JAK1 | P23458 | 2/20 | 0.75 |
| ▸ | BRD2 | P25440 | 2/20 | 0.75 |
| ▸ | JAK3 | P52333 | 2/20 | 0.75 |
| ▸ | BRD3 | Q15059 | 2/20 | 0.75 |
| ▸ | BRDT | Q58F21 | 2/20 | 0.75 |
| ▸ | BUB1B | O60566 | 1/20 | 0.75 |
| ▸ | RET | P07949 | 1/20 | 0.75 |
| ▸ | WEE1 | P30291 | 1/20 | 0.75 |
| ▸ | FLT3 | P36888 | 1/20 | 0.75 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31163098 | 0.98 | BRD4 (0.94) | BRD4JAK2JAK1BRD2JAK3 | |
| SCHEMBL265921 | 0.98 | BRD4 (0.94) | BRD4JAK2JAK1BRD2JAK3 | |
| SCHEMBL264965 | 0.98 | BRD4 (0.92) | BRD4JAK2JAK1BRD2JAK3 | |
| Hydrochloric Acid SCHEMBL264758 | 0.98 | BRD4 (0.92) | BRD4JAK2JAK1BRD2JAK3 | |
| SCHEMBL30306526 | 0.97 | BRD4 (1.00) | BRD4JAK2JAK1BRD2JAK3 | |
| SCHEMBL17526142 | 0.97 | BRD4 (1.00) | BRD4JAK2JAK1BRD2JAK3 | |
| SCHEMBL265805 | 0.93 | BRD4 (0.89) | BRD4JAK2JAK1BRD2JAK3 | |
| SCHEMBL17526323 | 0.88 | BRD4 (1.00) | BRD4JAK2JAK1BRD2JAK3 | |
| SCHEMBL30306481 | 0.88 | BRD4 (1.00) | BRD4JAK2JAK1BRD2JAK3 | |
| SCHEMBL17526215 | 0.88 | BRD4 (1.00) | BRD4JAK2JAK1BRD2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4673149-A1 | NEW COMPOUNDS AND TREATMENT OF RENAL CELL CARCINOMA | Trustlife Global Inc. (US) | 2026-01-07 | — | — | EP | disclosed |
| US-20250188041-A1 | NEW COMPOUNDS AND TREATMENT OF RENAL CELL CARCINOMA | Trustlife Global Inc. | 2025-06-12 | — | — | US | disclosed |
| CN-118804751-A | New compounds and treatment of renal cell carcinoma | 巴什生物技术公司 | 2024-10-18 | — | — | CN | disclosed |
| WO-2024179699-A1 | NEW COMPOUNDS AND TREATMENT OF RENAL CELL CARCINOMA | BASH BIOTECH INC. (US) | 2024-09-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250188041-A1 | NEW COMPOUNDS AND TREATMENT OF RENAL CELL CARCINOMA | RCC2, GLS, VHL | BRD4 2186/4885JAK2 1549/4885JAK1 2901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.